Paola Marcovecchio
Senior Principal Scientist Pfizer
I am currently a Senior Principal Scientist at Pfizer in the Immune Engager group, where we strive to deliver first in class cancer treatments. The focus of my work is to investigate novel therapeutics to generate a robust anti-tumor immune response and overcome acquired resistances. I have been at Pfizer since 2019, prior to which I completed my graduate studies at the La Jolla Institute for Allergy and Immunology. My scientific interests include dendritic cell: T cell crosstalk, confocal microscopy of tumor architecture, and amplifying or extending cytolytic capabilities of T cells within the tumor microenvironment.
Seminars
Thursday 17th September 2026
Beyond Bispecifics: Novel Modalities Increase the Therapeutic Window & Durability Of Next-Generation TCEs
9:00 am
- New TCE designs are necessary to crack the code of solid-tumor TCEs and address relapsed/refractory heme malignancies
- Better biological data packages are necessary to design avidity-driven modalities
- CD3 affinity needs to be developed in the context of the modality with more thoughtful clinical dosing regimens
